Long-read sequencing analysis of non-classical congenital adrenal hyperplasia prevalence and carrier frequency in Chinese polycystic ovarian syndrome patients

Adrenocortical hyperplasia is an autosomal recessive disorder characterized by congenital metabolic dysfunction, resulting in endocrine disturbances and abnormal sexual development (such as female masculinity), requiring lifelong hormonal therapy. Notably, non-classical congenital adrenal hyperplasia (NCCAH) exhibits clinical manifestations resembling polycystic ovary syndrome (PCOS), yet their therapeutic approaches in fertility treatment differ substantially. Importantly, NCCAH carries the risk of delivering offspring with severe adrenal hyperplasia, which presents far graver consequences than PCOS. Accurate differentiation between these two conditions is therefore crucial for proper clinical management. However, to date, no large-scale screening studies have been conducted to investigate the prevalence and carrier status of NCCAH among PCOS populations. A total of 1,372 suspected PCOS patients were genotyped by long-read sequencing in this study. To further clarify phenotypic characteristics, detailed clinical evaluation and laboratory analysis were conducted on 947 of these patients. The prevalence of NCCAH in suspected PCOS patients was 0.73‰ (95% CIs: 0.02–4.05‰; 1/1,372). The carrier rate for the CAH variants in PCOS patients was 4.45% (61/1,371, 95% CIs: 3.42–5.68%), of which 78.69% were CYP21A2 variants. The carrier frequencies for classic CAH and NCCAH in PCOS patients were 1.46% (95% CIs: 0.89–2.24%) and 2.04% (95% CIs: 1.36–2.94%), respectively. PCOS patients with hirsutism exhibited a significantly higher NCCAH carrier rate compared to those without hirsutism (3.90% vs. 0.37%, p<0.001). However, other clinical features such as irregular menstrual cycles, insulin resistance, and obesity showed no correlation with CAH carrier status. No significant differences in clinical or paraclinical characteristics were found among CAH carriers. PCOS patients had similar CAH carrier rates with the general population in China, and carriers of CAH variants are generally asymptomatic.

• Publication year

  2025

• Venue

  Journal of Ovarian Research

• Publication date

  2025-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13048-025-01824-xPMID 41219732PMCID 12606804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted long-read sequencing facilitates effective carrier screening for complex monogenic diseases including spinal muscular atrophy, α-/β-thalassemia, 21-hydroxylase deficiency, and fragile-X syndrome

  2025influential reference
• Long-read sequencing solves complex structure of CYP21A2 in a large 21-hydroxylase deficiency cohort.

  2024cited by this paper
• CYP21A2 Intron 2 Genetic Variants Might Be Associated with the Clinical Characteristics of Women with PCOS

  2024influential reference
• Improved genetic characterization of congenital adrenal hyperplasia by long-read sequencing compared with multiplex ligation-dependent probe amplification plus Sanger sequencing.

  2024cited by this paper
• Unexpectedly high mutation rate of cyp11b1 compared to cyp21a2 in randomly-selected turkish women: a large screening study

  2023cited by this paper
• Clinical application value of expanded carrier screening in the population of childbearing age

  2023influential reference
• Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.

  2023influential reference
• Long-read sequencing: An effective method for genetic analysis of CYP21A2 variation in congenital adrenal hyperplasia.

  2023cited by this paper
• OUP accepted manuscript

  2022influential reference
• Diagnosis and Treatment of Polycystic Ovary Syndrome.

  2022cited by this paper
• A capillary electrophoresis-based multiplex PCR assay for expanded carrier screening in the eastern Han Chinese population

  2022influential reference
• Congenital adrenal hyperplasia.

  2022cited by this paper
• Comprehensive Analysis of Congenital Adrenal Hyperplasia Using Long-Read Sequencing.

  2022cited by this paper
• Current and Novel Treatment Strategies in Children with Congenital Adrenal Hyperplasia

  2022cited by this paper
• Non-Classical Congenital Adrenal Hyperplasia-Causing Alleles in Adolescent Girls with PCOS and in Risk Group for PCOS Development

  2021cited by this paper
• Revised

  2020cited by this paper
• EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency

  2020cited by this paper
• Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

  2020cited by this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency.

  2019cited by this paper
• Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia.

  2019cited by this paper
• Issues with the Detection of Large Genomic Rearrangements in Molecular Diagnosis of 21-Hydroxylase Deficiency

  2019cited by this paper
• Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

  2018cited by this paper
• Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

  2018cited by this paper
• Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.

  2017influential reference
• Genetics of Congenital Adrenal Hyperplasia.

  2017cited by this paper
• Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome

  2015cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• The prevalence of endocrinopathies among Lebanese women presenting with hirsutism to an endocrine clinic.

  2014cited by this paper
• Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study.

  2014cited by this paper
• Genotype–phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency

  2013cited by this paper
• Prevalence of polycystic ovary syndrome in women in China: a large community-based study.

  2013cited by this paper
• Mapping single molecule sequencing reads using basic local alignment with successive refinement (BLASR): application and theory

  2012cited by this paper
• The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

  2009cited by this paper
• A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs.

  2008cited by this paper
• Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

  2006cited by this paper
• Hyperandrogenism in carriers of CYP21 mutations: the role of genotype

  2006cited by this paper
• Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls.

  2005cited by this paper
• Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

  2005cited by this paper
• Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population.

  2005cited by this paper
• Congenital adrenal hyperplasia.

  2005cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

  2004cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  2004cited by this paper
• Newborn screening for congenital adrenal hyperplasia.

  2001influential reference
• The role of heterozygosity for CYP21 in the polycystic ovary syndrome.

  2000cited by this paper
• 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study.

  2000cited by this paper
• Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico.

  2000cited by this paper
• Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.

  1999cited by this paper
• The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations.

  1999cited by this paper
• Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.

  1997cited by this paper
• Etiological review of hirsutism in 250 patients.

  1994cited by this paper
• Late‐onset congenital adrenal hyperplasia in women with hirsutism

  1992cited by this paper
• Assessment of the one hour adrenocorticotrophic hormone test in the diagnosis of attenuated 21-hydroxylase deficiency.

  1990cited by this paper
• Screening for late onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

  1990cited by this paper
• Congenital adrenal hyperplasia.

  1988cited by this paper
• Late-onset adrenal hyperplasia in hirsutism.

  1985cited by this paper
• The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women.

  1984cited by this paper

• No citing papers are available for this paper.